QUALIGEN THERAPEUTICS

Qualigen is a biotechnology company committed to developing new therapeutics for adult and pediatric patients with rare cancers, as well as expansion of its flagship... Qualigen Therapeutics, Inc. is a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. Our investigational QN-302 compound is a small molecule selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells; such binding could, by stabilizing the G4s against "unwinding," help inhibit cancer cell proliferation. The investigational compounds within Qualigen's family of Pan-RAS oncogene protein-protein interaction inhibitor small molecules are believed to inhibit or block the binding of mutated RAS genes' proteins to their effector proteins, thereby leaving the proteins from the mutated RAS unable to cause further harm. In theory, such mechanism of action may be effective in the treatment of about one quarter of all cancers, including certain..

Also known as: Qualigen, Qualigen Therapeutics, Inc., Qualigen, Inc

Primary location: Carlsbad United States